Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

TRX Gold Ord Shs V.TRX


Primary Symbol: T.TRX Alternate Symbol(s):  TRX

TRX Gold Corporation is a Canada-based company, which is advancing the Buckreef Gold Project. The Company is engaged in the exploration, development and production of mineral property interests in the United Republic of Tanzania. The Buckreef Project's prospects include Buckreef, Bingwa, Tembo, Anfield, Eastern Porphyry and Buziba. The Buckreef Project encompasses three main mineralized zones: Buckreef South, Buckreef Main and Buckreef North. The Company produces gold at its 1,000 tons per day processing plant. Its gold development operations include the Sulphide Development Project, in which the sulphide ore encompasses over 90% of the Buckreef Main Zone's two-million-ounce gold measured and indicated mineral resources. The Buckreef Project hosts an NI 43-101 measured and indicated mineral resource of over 35.88 million tons (MT) at 1.77 grams per ton (g/t) gold containing 2,036,280 ounces of gold and an inferred mineral resource of 17.8 MT at 1.11 g/t gold for 635,540 ounces of gold.


TSX:TRX - Post by User

Post by RCTflowon Nov 29, 2014 11:39pm
153 Views
Post# 23177993

Facts are fact and $1.40 usd target is low imo

Facts are fact and $1.40 usd target is low imo
  • With an existing diverse portfolio of products and the recent acquisition of Novartis' products, Tribute, a specialty pharma company, is chugging along towards positive EBITDA in 2015.
  • The higher margin primary care products (CAMBIA, Bezalip SR and Soriatane) have shown double digit growth since their launch and are just starting to pick up speed.
  • Based on Tribute’s streamlined operations and efficiency, along with a strong portfolio of products, expect Tribute to build significant value in the near term.
  • We are maintaining our Outperform rating with a target share price of $1.40.
<< Previous
Bullboard Posts
Next >>